In vitro anti-cancer activity of a novel microbial fermentation product on human carcinomas

CHUNG HIN CHUI1,2, ROBERTO GAMBARI3, FUNG YI LAU2, GREGORY YIN MING CHENG2, RAYMOND SIU MING WONG2, STANTON HON LUNG KOK1, JOHNNY CHEUK ON TANG1, IVY TUANG NGO TEO1,2, FILLY CHEUNG1,2, CHOR HING CHENG1,2, KWOK PING HO1,2, ALBERT SUN CHI CHAN1 and ALFONSO WONG4

1Anti-Cancer Research Center, Central Laboratory of the Institute of Molecular Technology for Drug Discovery and Synthesis, State Key Laboratory of Chinese Medicine and Molecular Pharmacology, Department of Applied Biology and Chemical Technology, The Hong Kong Polytechnic University; 2Department of Medicine and Therapeutics, Prince of Wales Hospital, The Chinese University of Hong Kong, P.R. China; 3ER-GenTech, Department of Biochemistry and Molecular Biology, Section of Molecular Biology, University of Ferrara, Italy; 4International Naturopathic Cancer Research Institute, P.R. China

Received October 24, 2005; Accepted December 30, 2005

Abstract. The possible anti-proliferation and cell death induction potential of a novel microbial fermentation extract named as oncogen XP-180 (or simply as XP-180) was tested on three human solid tumour carcinoma cell lines (non-small cell lung cancer A549, breast cancer MDA-MB231, liver adenocarcinoma SK-Hep1) and on the acute myelogenous leukaemia KG1a cell line. Anti-proliferative activity of XP-180 was observed on all of these cancer cell lines with comparable efficiency and in a dose-dependent manner. Morphological investigation further suggested that common features of apoptosis, including cell shrinkage and rounding, are present in XP-180 treated cells. Loss of adhesion properties of these solid tumour cell lines was observed upon XP-180 incubation. Anchorage-dependent clonogenicity assay on solid tumour cell lines and semi-solid methylcellulose colony formation assay on leukaemia cell line further revealed that XP-180 strongly inhibited the regeneration potential of these cancer cells. Using KG1a as an experimental model system, XP-180 was shown to stimulate the activity of caspase 3, 8 and 9 without significant change in caspase 6 activity. Furthermore, XP-180 readily induced collapse of mitochondrial membrane potential after 2 h of incubation. However, the use of the generic caspase specific inhibitor Z-VAD-FMK does not significantly reverse XP-180 mediated cell death. The results obtained suggest that XP-180-mediated cancer cell death could involve mitochondria and both caspase-dependent and -independent pathways. Therefore, XP-180 is an efficient anti-cancer regimen in vitro.

Introduction

Cancer is still one of the most common fatal diseases in the human population. In Hong Kong, lung carcinoma is the first life-threatening pathology among carcinomas (1). Lung carcinoma should be considered with great attention from the epidemiological point of view, since both active and passive smokers are believed to have a higher incidence of getting this pathology than non-smokers (1). Another important neoplastic disease is breast cancer, more common in Western part of the world, but the rate is increasing in East Asia (2). The rate of occurrence of hepatocellular carcinoma (HCC) is relatively high in East Asia (1), in association with hepatitis B infection and liver cirrhosis (3,4). Due to environmental pollution, leukaemic diseases are still very frequent (6). Thus, drugs exhibiting pharmacological activity against these forms of neoplasias are of great interest.

The study of microbial fermentation products as anti-cancer regimens is the object of great efforts, in addition to natural herbal medicines, as their qualities are under stringent control in both laboratory and industrial settings (7). We have demonstrated that the effective microorganism extract (EM-X) and Phaffia rhodozyma (Xanthophyllomyces denrorhous) extract fermented from brewer malt waste are active in vitro in growth inhibition and induction of cell death on several types of cancer cells (8-10). Both extracts possess strong anti-oxidative activity. Oncogen XP-180 is a novel microbial
fermentation extract resulting from the biological activities of >180 strains of bacteria, including *Lactobacillus Acidophilus*, LC90-18 and *Lactobacillus gasseri* ATCC.

We screened for the possible anti-cancer potential of XP-180 several solid tumours, including non-small cell lung cancer, breast cancer, hepatoma and acute myelogenous leukaemia (AML) cell lines. Our results suggest that XP-180 is an effective anti-proliferative and apoptosis inducing agent in the cancer cell lines tested. XP-180 significantly reduced the regeneration potential of cancer cells. Mitochondrion is involved while both caspase-dependent and -independent pathways are active in XP-180 induced apoptosis.

Materials and methods

**Determination of concentration of XP-180.** The original brownish fluid of XP-180 (kindly provided by Dr Alfonso Wong) was mixed with absolute ethanol. The mixture was then warmed in a round bottomed flask using a rotatory evaporator in a warm water bath. When all fluid was evaporated, the net weight of the dried extract was measured. The volume of fluid from each step was also recorded. The concentration of XP-180 extract was calculated to be approximately 24 mg/ml.

**Cell lines and cell culture condition.** The cell lines employed in this study included the non-small cell lung cancer A549, the breast cancer MDA-MB231, the liver adenocarcinoma SK-Hep1 and the acute myelogenous leukaemia KG1a cell lines. All of them were obtained from American Type Culture Collection. They were maintained routinely in minimum essential medium (MEM) (JRH Biosciences) supplemented with 5% fetal bovine serum (HyClone) together with penicillin and streptomycin ( invitrogen). Cell lines were kept in a 5% carbon dioxide humidified incubator at 37°C.

**Primary cultures from non-malignant haematological disordered bone marrow.** After informed consent, bone marrow samples were obtained from three patients with non-malignant haematological disorder. Mononuclear cells were enriched and harvested immediately after Ficoll density centrifugation (Amersham, General Electric) and washed with phosphate-buffered saline (PBS). Cell pellets were resuspended in RPMI-1640 culture medium and cell viability was determined by trypan blue exclusion assay.

**Anti-proliferative and cytotoxic tests.** The Cytolite chemiluminometric kit purchased from Perkin-Elmer was used to test the anti-proliferative and cytotoxic activities of XP-180. Briefly, different cell lines were seeded in a 96-well microtiter plate on the first day. On the second day, growth medium was changed and different concentrations of XP-180 [starting from 10% (v/v) by volume ratio, i.e. 2.4 mg/ml] was added. In each case, 10% (v/v) of sterile water was used as control. Serial dilutions of XP-180 were performed in water [10% (v/v) of final volume]. After 48 h, the resulting luminescence values from water control and concentrated XP-180 treated cells were measured using a Victor^2^V multilabel 1420 counter (Perkin-Elmer) according to the instruction manual provided.

**Morphological changes of XP-180 treated cell.** Cancer cells were seeded as mentioned before and then 10% (v/v) of XP-180 was added. Any morphological changes after 48 h were determined under an inverted microscope (11, 12).

**Colony formation assay of solid tumour cell lines.** The cancer cell lines A549, MDA-MB231 and SK-Hep1 were incubated with 5% (v/v) of XP-180 plus 5% (v/v) sterile distilled water or 10% (v/v) XP-180 for 6 days. Untreated control cells were incubated with 10% (v/v) of sterile distilled water only for 6 days. Culture plates were washed, then stained with methylene blue, washed again, and then photographed.

**Colony formation assay of KG1a and bone marrow cells.** KG1a AML cells and mononuclear cells isolated from bone marrow samples were counted and cultured in methylcellulose (Stemcell Technology, Canada) with either vehicle or 10% (v/v) of XP-180 for 14 days. Viable colony formation units (CFU) [reducing 3-(4,5-dimethylthiazolyl)-2,5-diphenyl-tetrazolium bromide (MTT)] were then scored under an inverted microscope.

**Caspase activity assay.** To study whether caspase 3, 6 and 8 protease activities were increased after 24 h of XP-180 treatment on KG1a AML cells, we used a time resolved fluorescence technology based caspase 3, 6 and a caspase 8 activity kit purchased from Lance, Perkin-Elmer (Finland). Briefly, XP-180 treated cells were washed with PBS and then total cellular protein extracts were prepared and quantitated by the Bradford method using bovine serum albumin as calibration. Caspase 3, 6 and 8 specific substrates and detection buffer were added to equal amount of total cancer cell protein extract and individual caspase activity was analysed according to the instruction manual provided. The resulting relative fluorescence units were compared with untreated control (13). For caspase 9 activity, we used the Caspase-Glo 9 assay kit purchased from Promega. The assay procedure was performed as described before, except that caspase 9 activity was determined by a homogeneous luminescent assay.

**Dепolarization of the mitochondrial membrane potential.** We used JC-1 as the detection probe (Molecular Probes) for the change of mitochondrial membrane potential. Briefly, after incubating KG1a AML cells with XP-180 for 2 h, they were stained with JC-1. Mitochondria with a high membrane potential retained JC-1 as J-aggreate and gave a red signal. When there was depolarization of mitochondrial membrane potential, JC-1 was lost from the mitochondria and a shift from red to green resulted. Thus, the change of green/red fluorescence intensity ratio from low to high value indicated that there was a collapse in the mitochondrial membrane potential.

**Caspase dependency cytotoxicity assay.** To determine whether XP-180 mediated induction of apoptosis also involve caspase-independent pathways, KG1a AML cells were pretreated with caspase inhibitor Z-VAD-FMK, at concentration of 30 μM. Afterwards, either 5% (v/v) or 10% (v/v) of XP-180 was added and cancer cells were further incubated for 48 h. The...
resulting cellular viability was then quantified by using the Cytolite kit.

Results and Discussion

Effects of XP-180 on cellular proliferation and cytotoxic activity. The results shown in Figs. 1A and 2 clearly indicate that XP-180 effectively exerts anti-proliferative and cytotoxic effects on A549 lung cancer, MDA-MB231 breast cancer and SK-Hep1 hepatoma cell lines. The effects were dose dependent. A maximum cytotoxic activity was found at 10% (v/v), experimental conditions at which XP-180 exerts about 70-80% of cytotoxicity on the three tumour cell lines (Fig. 1A). Characteristic features of cell death, including cell shrinkage, rounding and loss of adhesion potential were observed (Fig. 2).

On the other hand, only about a 40% growth inhibitory effect on three samples of non-malignant haematological disordered bone marrow cells. The conditions of treatment were the same as those employed for solid tumour cell lines. Results are shown as mean ± SD of triplicate tests from a representative single experiment.

Effects of XP-180 on colony formation potential. After incubation of the solid tumour and KG1a AML cells with XP-180, we analysed the effects of XP-180 on their colony formation potential. The results obtained demonstrated that concentrated XP-180 is able to effectively reduce their regeneration potential. A dose-dependent relationship (from 1.22 mg/ml to 2.44 mg/ml) was found in the case of A549, MDA-MB231 and SK-Hep1 cancer cells (Fig. 3A-C). At the dosage of 10% (v/v) (2.44 mg/ml), complete loss of colony formation was observed for all the solid tumour cell lines employed (Fig. 3A-C). In the case of KG1a, a complete inhibition on the regeneration potential was also found at the dose of 10% (v/v) of XP-180 (Fig. 3D).

When the experiments were performed on primary cultured bone marrow cells, concentrated XP-180 was found to reduce also the regeneration potential of bone marrow cells isolated from patients with non-malignant haematological disorders (Fig. 3D, lower pair). However, the degree of inhibition of colony formation when bone marrow cells isolated from patients with non-malignant haematological disorders were employed was not as strong as the inhibition observed with KG1a AML cells.

Activity of caspase 3, 6, 8 and 9 following XP-180 treatment. After demonstrating that XP-180 was active on cancer cell lines, we focused our experiments on the investigation of...
possible mechanism(s) of action of XP-180, using the AML KG1a cell line as the experimental model system. Since caspases are probably the most important effector molecules triggering apoptosis, we attempted to determine whether XP-180 is able to activate endogenous caspase activity at a concentration of 10% (v/v). The results obtained demonstrate that caspase 3 was significantly activated while no significant changes in the proteolytic activity mediated by caspase 6 was detected (Fig. 4A).

Caspase 8 and 9 are important for cascade activation of downstream caspase activity. After 10% (v/v) XP-180 stimulation, both caspase 8 and 9 were found to be activated. Thus our results suggested that XP-180 first activated caspase 8 and 9, which in turn stimulated caspase 3 and leading to apoptosis of tumour cells (Fig. 4B).

XP-180 induces depolarization of the mitochondrial membrane potential. Since caspase 9 activity is associated with XP-180 induced apoptosis, it was highly possible that mitochondria are also involved. Thus, we tested whether there was any collapse in mitochondrial membrane potential in XP-180 treated cells. As shown in Fig. 4A, XP-180 at 10% (v/v) readily enhanced mitochondrial membrane collapse.
Co-incubation with caspase inhibitor Z-VAD-FMK could not protect mitochondria from depolarization (Fig. 5A). Therefore, it is possible that mitochondrial alterations are essential for the action of XP-180.

Caspase 3-independent pathways are also involved in XP-180-mediated apoptosis. Since we demonstrated that caspase 3, 8 and 9 were stimulated by XP-180, we determined whether the block of induction of these apoptotic mediators could inhibit cell death. Using the Cytolite cytotoxicity kit, we analyzed whether the caspase inhibitor Z-VAD-FMK could reverse the action of XP-180 on AML KG1a cells. As shown in Fig. 5B, the presence of caspase inhibitor at a concentration effectively suppressing the XP-180 mediated increase of caspase activity (right side of Fig. 4) could not significantly reverse the action of XP-180 when used at either 5% (v/v) or 10% (v/v) (Fig. 5B). Therefore, we concluded that both caspase-dependent and -independent pathways are active in XP-180 mediated apoptosis.

Many naturally occurring products are shown to be useful in cancer treatment. These include many traditional Chinese herbal medicines such as anomalous fruit extract of Camellia sinensis (15), herbal medicines such as Camellia sinensis (17). Moreover, green tea, derived from Camellia sinensis is considered an anti-cancer preventive agent (18). As alternative cancer therapy becomes more recognized and acceptable, the uses of microbial fermentation products and herbal medicines should provide cancer patients a supplementary treatment in the foreseeable future, in addition to conventional chemotherapy. The results herein reported support the concept that anti-cancer agents can be reproducibly found in natural products (19).

Acknowledgements

We acknowledge the Hong Kong Polytechnic University (Area of Strategic Development Fund, HKPU), the University Grants Committee (Areas of Excellence Scheme) of the Hong Kong Polytechnic University (Project No. AoE-P-10/01) and a Niche Area grant (Area of Strategic Development Fund, HKPU), the University Grants Committee (Areas of Excellence Scheme) of the Hong Kong Polytechnic University (Project No. AoE/P-10/01) and a Niche Area grant (Area of Strategic Development Fund, HKPU) for their donation to Haematology Research Funding in Haematology Division, Department of Medicine and Therapeutics, Prince of Wales Hospital (PWH), The Chinese University of Hong Kong (CUHK). Drs F.Y.L. and C.H.C. are the honourary tutors kindly offered by Professor Joseph J.Y. Sung and Professor G.Y.M.C. from Department of Medicine and Therapeutics, PWH, CUHK. Dr C.H.C. was supported by the post of ‘Scientific Officer’ offered by Professors K.Y. Wong and A.S.C.C. Professor R.G. is granted by AIRC and by UE (Interventi Strutturali Obiettivo 2).

References